<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732625</url>
  </required_header>
  <id_info>
    <org_study_id>FIMHCSBR-2017</org_study_id>
    <nct_id>NCT03732625</nct_id>
  </id_info>
  <brief_title>Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study</brief_title>
  <acronym>NEARQD</acronym>
  <official_title>Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, multicenter, non randomized, single arm, pilot trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, multicenter, non randomized, single arm, pilot trial. The study is aimed at patients&#xD;
      infected with HIV in triple antiretroviral therapy based on Dolutegravir (DTG) who experience&#xD;
      neuropsychological adverse effects related to the treatment. After signing the informed&#xD;
      consent, DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs&#xD;
      that constituted the triple therapy established before the inclusion of the patient in the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, open, non-randomized pilot trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate improvement in neuropsychiatric symptoms at 12 weeks (Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate improvement in neuropsychiatric symptoms: grade 1 to 4 of DAIDS scale. higher values represent a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric symptoms</measure>
    <time_frame>24 weeks</time_frame>
    <description>Presence and Intensity of neuropsychiatric symptoms (visual scale 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interruptions of the medication for any reason</measure>
    <time_frame>24 weeks</time_frame>
    <description>Interruptions of the medication due to adverse effects, virological failure, or any other reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (WHOQoL-bref questionnaire)</measure>
    <time_frame>24 weeks</time_frame>
    <description>World Health Organization Quality of Life: 1-100 in 4 domains. 100 best score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the result in the Hospital, Anxiety and Depression (HAD) scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hospital, anxiety and depression: 0 y 7 indicates no case, between 8 &amp; 10 indicates doubtful case and scores of 11 and above are possibly anxiety and depression cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the result on the Pittsburgh Sleep Quality Index (PSQI) scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pittsburgh Sleep Quality Index: Score 0 to 21 points. &quot;0&quot; indicates ease of sleeping and &quot;21&quot; severe difficulty in all areas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the result in the Epworth scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>Diurnal drowsiness: If score is less than 6 points, daytime sleepiness is low or absent; between 7 and 8, is in the average of the population and if it is higher than 9 its drowsiness is excessive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the result in the COLUMBIA-SUICIDE SEVERITY RATING (CSSR) scale</measure>
    <time_frame>24 weeks</time_frame>
    <description>COLUMBIA-SUICIDE SEVERITY RATING SCALE: progressive score depending of each question answer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imagigng (MRI) analysis for 10 of the patients recruited at the Costa del Sol Hospital (pilot subestudy)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Identify patterns of different metabolic marker 18F-fluorodeoxyglucose (18F-FDG) uptake in patients suffering from central nervous system toxicity in relation to the use of Dolutegravir after replacement with Raltegravir.&#xD;
Observe if the anatomic-functional pattern of these patients changes after the substitution of Dolutegravir by Raltegravir.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Substitution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Infection with chronic HIV-1.&#xD;
&#xD;
          -  On triple therapy antiretroviral therapy based on abacavir/lamivudine (ABC/3TC) or&#xD;
             tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or tenofovir&#xD;
             alafenamide/emtricitabine (TAF/FTC), whose third component is DTG in a dose of 50 mg /&#xD;
             day.&#xD;
&#xD;
          -  Presence of neuropsychiatric symptoms (insomnia, sleep disturbances, reduced&#xD;
             concentration, dizziness, headaches, depression, restlessness or nervousness) with an&#xD;
             intensity ≥ 2 on the DAIDS scale.&#xD;
&#xD;
          -  Written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnant women, nursing or of childbearing age who want to get pregnant.&#xD;
&#xD;
          -  Concomitant use of any medication with potential risk of interaction with the therapy&#xD;
             under study.&#xD;
&#xD;
          -  Intolerance, hypersensitivity or previous resistance to the therapy under study or&#xD;
             presence of any contraindication of it.&#xD;
&#xD;
          -  Subjects in therapy with immunosuppressants or chemotherapy with cytotoxics, including&#xD;
             interferon and interleukin-2 at the time of their inclusion in the study.&#xD;
&#xD;
          -  Abuse of alcohol or any other substance that may interfere with adherence to&#xD;
             treatment.&#xD;
&#xD;
          -  Subjects who are participating in any other clinical study with the exception of those&#xD;
             in which the treatment under study has been suspended for more than 12 weeks.&#xD;
&#xD;
          -  AIDS event at the time of diagnosis of HIV infection or in the 3 months prior to its&#xD;
             inclusion&#xD;
&#xD;
          -  Any other clinical condition or previous treatment that makes the subject unsuitable&#xD;
             for the study or that compromises their ability to comply with the treatment dosing&#xD;
             requirements.&#xD;
&#xD;
          -  History of mental illness or diagnosis of neuropsychological symptoms prior to the use&#xD;
             of DTG.&#xD;
&#xD;
          -  Presence of genotypic mutations that confer resistance to ABC, TDF / TAF, 3TC or FTC.&#xD;
&#xD;
          -  Chronic liver disease in the cirrhosis phase (either by ultrasound criteria or&#xD;
             fibroscan ≥ 14.5 KPa)&#xD;
&#xD;
          -  Consumption of tobacco ≥ 20 cigarettes / day.&#xD;
&#xD;
        Additional Exclusion Criteria (for patients recruited at the Costa del Sol Hospital in&#xD;
        Marbella only):&#xD;
&#xD;
          -  History or diagnosis of claustrophobia, or inability to lie flat on the back inside&#xD;
             the positron emission tomograph or MRI chamber for a period of 20 minutes.&#xD;
&#xD;
          -  Contraindication to perform an MRI, including the presence of a cardiac pacemaker or&#xD;
             other electronic device or ferromagnetic metallic foreign bodies in vulnerable&#xD;
             positions evaluated by a standard questionnaire prior to MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Olalla, PhD</last_name>
    <role>Study Director</role>
    <affiliation>SAS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Luque</last_name>
    <phone>+34 951 29 19 77</phone>
    <email>gloria.luque@fimabis.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alejandro Pérez</last_name>
    <phone>+34 951 29 14 47</phone>
    <email>alejandro.perez@fimabis.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Costa del Sol University Hospital</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <investigator>
      <last_name>Esteban Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínic University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <investigator>
      <last_name>Esteban Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Carlos Clinical Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <investigator>
      <last_name>Vicente Estrada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>neuropsychological adverse effects</keyword>
  <keyword>Raltegravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

